AI, human intelligence, and the future of healthcare communications
The debate around AI in healthcare has settled into a familiar groove. Both sides are right - but are both missing the point?
Independent strategic healthcare communications leader, with more than 20 years across science, medical affairs, and marketing. I work directly with pharma, biotech, and agencies - no layers, no dilution.
Expertise runs deeper than technical knowledge. It is built through years of shaping strategy, solving challenges, pursuing opportunity, and delivering results.
With a background spanning academic research, healthcare communications, and leadership, I offer a distinct combination of scientific depth, strategic direction, and commercial insight.
Clients range from companies seeking senior strategic direction and programme leadership, to those requiring hands-on support across their most demanding and complex portfolios.
Providing senior direction and leadership to strengthen product and portfolio positioning, differentiation, performance, and launch
Supporting business growth through pitch development, proposal strategy, and new business and pipeline planning.
Strengthening scientific and strategic depth across scientific, medical and marketing communications, from team leadership to executive communications.
Rare and ultra-rare disease, infectious disease (vaccines), oncology, CVRM, respiratory, haematology, ophthalmology, immunology, metabolic, gastroenterology, women's health.
From a PhD in pioneering genetic biotechnology to executive leadership, my career has been shaped by curiosity and a passion to make a difference. I've stayed close to the science, while building strategic and commercial depth across all aspects of healthcare communications, supporting products from early development through to launch - with the privilege of supporting some of our industry's most significant innovations.
Nuclear Medicine
Industry sponsored.
Pharmacology
The debate around AI in healthcare has settled into a familiar groove. Both sides are right - but are both missing the point?
Precision medicine didn't begin in oncology, it started in rare diseases - today targeted biology and precision medicine is blurring boundaries between the two.